



ADVANSOURCE BIOMATERIALS DECLARES POLYMER PRODUCTS COMPLY WITH CURRENT EUROPEAN COUNCIL DECISION GUIDELINES

Wilmington, MA. February 8, 2010... AdvanSource Biomaterials Corporation (NYSE Amex: ASB), a leading developer of advanced polymer materials for a broad range of medical devices, today announced that its polymer product lines are compliant with measures applying to the processing of certain animal waste to protect against transmissible spongiform encephalopathies as set forth in European Council Decision 1999/534/EC.

Khristine Carroll, AdvanSource's Senior Vice President of Commercial Operations, stated, "AdvanSource is committed to upholding the highest risk assessment of its polymer products through rigorous processes and performance criteria while advocating efficient and effective control measures at every step of our manufacturing process. We recognize that the risk of infectious agent contamination, such as TSE and BSE, is mitigated through controlled sourcing and qualified evaluation of all our starting steps. Accordingly, we have undertaken a complete review of our materials, processes and raw material suppliers to proactively respond to the device industries growing concern regarding this issue. We are proud of the initiatives we take to respond to the concerns of our growing number of medical device customers in a proactive and timely manner and the partnerships these customers have offered us."

About AdvanSource Biomaterials Corporation

AdvanSource Biomaterials Corporation manufactures advanced polymer materials which provide critical characteristics in the design and development of medical devices. The Company's biomaterials are used in devices that are designed for treating a broad range of anatomical sites and disease states. AdvanSource's business model leverages its proprietary materials science technology and manufacturing expertise in order to expand its product sales and royalty and license fee income. More information about AdvanSource is available at its website: www.advbiomaterials.com.

Forward-Looking Statements

AdvanSource believes that this press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could cause results to differ materially from the forward-looking statements. For further information on such risks and uncertainties, you are encouraged to review AdvanSource's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended March 31, 2009 and its Quarterly Reports on Form 10-Q for the quarters ended June 30, 2009 and September 30, 2009. AdvanSource assumes no obligation to update any forward-looking statements as a result of new information or future events or developments, except as required by law.



For further information contact:

AdvanSource Biomaterials Corporation

Khristine Carroll, Sr. VP of Commercial Operations

978-657-0075, ext 134

kcarroll@advbiomaterials.com

David Volpe, Acting CFO

(978) 657-0075, ext. 103

dvolpe@advbiomaterials.com